

17° Meeting



CardioLucca
Heart Brings Heart 2023

Lucca, 22-24 Giugno 2023
Centro Congressi Auditorium San Francesco

Nuove frontiere e vecchie sfide nell'ablazione della fibrillazione atriale

Antonio Di Monaco



Ente Ecclesiastico
Ospedale Generale Regionale

MIULLI



17° Meeting


CardioLucca
Heart Brings Heart 2023




Lucca,
22-24 Giugno
2023

Centro Congressi
Auditorium San Francesco

Fibrillazione atriale: epidemiologia



Projected increase in AF prevalence among elderly in EU 2016-2060



ESC guidelines



17° Meeting


CardioLucca
Heart Brings Heart 2023



Lucca,
22-24 Giugno
2023

Centro Congressi
Auditorium San Francesco

Linee Guida ESC sulla Fibrillazione atriale





17° Meeting


CardioLucca
Heart Brings Heart 2023



Lucca,
22-24 Giugno
2023

Centro Congressi
Auditorium San Francesco

Fibrillazione atriale Potenziali elettrici delle Vene Polmonari




Haissaguerre M, N Engl J 1998




17° Meeting
CardioLucca
Heart Brings Heart 2023



Lucca,
22-24 Giugno
2023
Centro Congressi
Auditorium San Francesco



Atrial fibrosis as a dominant factor for the development of atrial fibrillation: facts and gaps



Europace (2020) 22, 342–351





17° Meeting
CardioLucca
Heart Brings Heart 2023




Lucca,
22-24 Giugno
2023

Centro Congressi
Auditorium San Francesco



Fibrillazione atriale parossistica



Fibrillazione atriale persistente



17° Meeting
CardioLucca
Heart Brings Heart 2023



Lucca,
22-24 Giugno
2023
Centro Congressi
Auditorium San Francesco

**Isolamento elettrico delle vene
polmonari**

Analisi substrato aritmico

Lesioni transmurali e continue

Lesioni permanenti

Complicanze

Nuove tecnologie









17° Meeting
CardioLucca
Heart Brings Heart 2023



Lucca,
22-24 Giugno
2023
Centro Congressi
Auditorium San Francesco

Mappaggio multielettrodo





17° Meeting


CardioLucca Heart Brings Heart 2023



Lucca,
22-24 Giugno
2023

Centro Congressi
Auditorium San Francesco

CARTOFINDER





17° Meeting

CardioLucca Heart Brings Heart 2023



Lucca,
22-24 Giugno
2023

Centro Congressi
Auditorium San Francesco

Ablazione



One shot

Less operator dependent



Fast



AF as «gym» for young electrophysiologists



Ability to treat unexpected arrhythmias




Carto guided transeptal puncture



Fits all PV anatomies



Point by point







Pulmonary Vein Isolation With Very High Power, Short Duration, Temperature-Controlled Lesions

The QDOT-FAST Trial

Vivek Y. Reddy, MD,^{a,b} Massimo Grimaldi, MD,^c Tom De Potter, MD,^d Johan M. Vijgen, MD,^e Alan Bulava, MD, PhD,^f Mattias Francis Duytschaever, MD,^g Martin Martinek, MD,^h Andrea Natale, MD,ⁱ Sébastien Knecht, MD, PhD,^g Petr Neuzil, MD, PhD,^b Helmut Püllerfellner, MD^h

FIGURE 1 The vHPSD Catheter





17° Meeting

CardioLucca

Heart Brings Heart 2023



Lucca,
22-24 Giugno
2023

Centro Congressi
Auditorium San Francesco

A

Standard



B

High-power Short-Duration



Resistive

Conductive

Resistive

Conductive



High-Power and Short-Duration Ablation for Pulmonary Vein Isolation

Biophysical Characterization





JACC: CLINICAL ELECTROPHYSIOLOGY
© 2019 THE AUTHORS. PUBLISHED BY ELSEVIER ON BEHALF OF THE AMERICAN
COLLEGE OF CARDIOLOGY FOUNDATION. THIS IS AN OPEN ACCESS ARTICLE UNDER
THE CC BY-NC-ND LICENSE (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).


VOL. 5, NO. 7, 2019



Pulmonary Vein Isolation With Very High Power, Short Duration, Temperature-Controlled Lesions

The QDOT-FAST Trial

Vivek Y. Reddy, MD,^{a,b} Massimo Grimaldi, MD,^c Tom De Potter, MD,^d Johan M. Vijgen, MD,^e Alan Bulava, MD, PhD,^f Matthias Francis Duytschaever, MD,^g Martin Martinek, MD,^h Andrea Natale, MD,ⁱ Sébastien Knecht, MD, PhD,^j Petr Neuzil, MD, PhD,^b Helmut Püller, MD^h





17° Meeting
CardioLucca
Heart Brings Heart 2023



Lucca,
22-24 Giugno
2023

Centro Congressi
Auditorium San Francesco



Received: 14 February 2020 | Revised: 23 June 2020 | Accepted: 6 July 2020
DOI: 10.1111/jce.14683

ORIGINAL ARTICLES

WILEY

Electroanatomic guidance versus conventional fluoroscopy during transseptal puncture for atrial fibrillation ablation

Federica Troisi MD, PhD | Federico Quadrini MD | Antonio Di Monaco MD |
Nicola Vitulano MD | Rosa Caruso DNP | Pietro Guida PhD |
Tommaso Langialonga MD | Massimo Grimaldi MD, PhD



J Cardiovasc Electrophysiol. 2020;31:2607–2613



17° Meeting

CardioLucca
Heart Brings Heart 2023




Lucca,
22-24 Giugno
2023

Centro Congressi
Auditorium San Francesco

Multi-electrode RF balloon


Spherical, compliant balloon that
conforms to varied
PV anatomy

10 irrigated
electrodes to
deliver customized RF energy
from all or selected electrode(s)
enabling 'single shot' or
segmental ablation



Compatible with
CARTO®3 Mapping
System to reduce
fluoroscopy

Over-the-wire
3F diagnostic
catheter for real time
PVI validation




Radiance: First in human study

- **40 patients enrolled and 39 treated by 9 operators (5 EU and 4 USA)**
 - 4 sites in UK, Italy and Czech Republic
- **100% isolation of PVs with balloon only (no focal touch-up needed)**
 - 79.6% one shot isolation of targeted PVs
- **40.5 min balloon dwell time in left atrium**
- **17.5 min fluoro time**
- **4.6% (7/150 PVs) reconnection rate**



Pulmonary Vein Isolation with the Novel Radiofrequency Balloon in Paroxysmal Atrial Fibrillation Patients - The Multicentre SHINE Study

PATIENT ENROLLMENT	PULMONARY VEIN ISOLATION (PVI)	12 MONTHS FOLLOW-UP
MULTICENTRE  EUROPEAN HOSPITALS	CIRCUMFERENTIAL SEGMENTAL  OR	SAFETY PROFILE 1.2% PRIMARY ADVERSE EVENT (n=1 Retroperitoneal bleed)
PATIENT INCLUSION  PATIENTS WITH SYMPTOMATIC PAROXYSMAL ATRIAL FIBRILLATION Age 18-75 years First-time ablation LA diameter ≤50 mm, LVEF ≥40%	PROCEDURAL EFFICIENCY 99.7% PVI WITH BALLOON ALONE 87.6MIN PROCEDURE TIME, MEAN	12-MONTH EFFECTIVENESS  12-MONTH FREEDOM FROM SYMPTOMATIC ATRIAL ARRHYTHMIA RECURRENCE* No significant site variation in 12-month freedom from symptomatic atrial arrhythmia recurrence 38.0% of patients on Class I/II AAD at 12 months, corresponding to a 32.8% decrease from baseline *Based on binomial analysis with stringent arrhythmia monitoring



17° Meeting




CardioLucca

Heart Brings Heart 2023

Lucca,
22-24 Giugno
2023


Centro Congressi
Auditorium San Fa






Irreversible electroporation


PEF Energy is delivered in a series of short, high-voltage, bipolar, biphasic pulses lasting fractions of a second




Non-Thermal ablation minimizes the risk of typically thermal induced risks and harms



Char



Steam Pop



AEF



Phrenic Nerve
Palsy



PV Stenosis




17° Meeting
CardioLucca
Heart Brings Heart 2023




Lucca,
22-24 Giugno
2023

Centro Congressi
Auditorium San Francesco



Cellular impact depends on the amount of energy (creating **a tissue specific effect**) and the **pulse amplitude & duration**



Electron microscope images of RBCs from: Donald C. Chang et al, Changes in membrane structure induced by electroporation as revealed by rapid-freezing electron microscopy, Biophys. J. 1990



17° Meeting

CardioLucca
Heart Brings Heart 2023



Lucca,
22-24 Giugno
2023

Centro Congressi
Auditorium San Francesco

Time Course of Irreversible Electroporation Lesion Development Through Short- and Long-Term Follow-Up in Pulsed-Field Ablation–Treated Hearts

Massimo Grimaldi , MD, PhD; Antonio Di Monaco , MD; Tara Gomez , PhD; Dror Berman, BS;
Keshava Datta, PhD; Tushar Sharma, MD; Assaf Govari, PhD; Andres Altmann , MSc; Luigi Di Biase , MD

Circ Arrhythm Electrophysiol. 2022;15:e010661.1



17° Meeting



Lucca.

Ca
Hear**Table 2. Study Results Summary**

	Subacute; n=6	Chronic study; n=4
Mean survival time, d, \pm SD	9 \pm 0	28.5 \pm 0.5
Mean PV diameter change, %, \pm SD	14.5 \pm 12.0%	11.8 \pm 13.3%
Mean lesion depth, mm, \pm SD	3.2 \pm 0.9	2.8 \pm 0.8
Mean lesion width, mm, \pm SD	16.1 \pm 3.6	17.1 \pm 8.9
Acute PV isolation (RIPV and RSPV)	12/12 (100%)	7/7(100%)*
Follow-up PV isolation	12/12 (100%)	6/6 (100%)
Acute SVC isolation	6/6 (100%)	4/4 (100%)
Follow-up SVC isolation	6/6 (100%)	4/4(100%)

PV indicates pulmonary vein; RIPV, right inferior pulmonary vein; RSPV, right superior pulmonary vein; and SVC, superior vena cava.

*RSPV isolation was not performed for one swine, resulting in 7 evaluable veins for the chronic cohort.



17° Meeting

CardioLucca Heart Brings Heart 2023



Lucca,
22-24 Giugno
2023

Centro Congressi
Auditorium San Francesco




Figure 4. Histological analysis of chronic cohort.

A, Posterior wall. Green dotted line denotes healed ablated area showing no adverse changes, arrow denotes thin neoendocardium, arrowhead denotes healed ablation with mild fibrosis, back box denotes area detailed in **B**. **B**, Double arrow denotes mature endothelialized fibromuscular neoendocardium (healed endocardium), arrows denote intact autonomic nerves, arrowhead denotes intact arteriole within the healed ablated area. **C**, Posterior wall. Green dotted line denotes healed ablated area showing no adverse changes, arrow denotes thin neoendocardium, arrowheads denote healed ablation with mild fibrosis.



17° Meeting

CardioLucca Heart Brings Heart 2023



Lucca,
22-24 Giugno
2023

Centro Congressi
Auditorium San Francesco




Figure 5. Histological analysis after 28 days from pulsed-field ablation.

A. Right superior pulmonary vein. Green dotted line= healed ablated area showing no adverse changes. back box= area detailed in **B.** **B.** Double arrows denote mature endothelialized fibromuscular neoendocardium (healed endocardium), arrows denote intact autonomic nerves, arrowheads= intact arterioles within the healed ablated area. **C.** Superior vena cava. Green dotted line denotes healed ablated area showing no adverse changes, arrow= thin neoendocardium, arrowhead denote healed ablation with slight fibrosis.



17° Meeting

CardioLucca
Heart Brings Heart 2023



Lucca,
22-24 Giugno
2023


Centro Congressi
Auditorium San Francesco

Danno Esofageo

Pulsed field ablation selectively spares the oesophagus during pulmonary vein isolation for atrial fibrillation

Cochet et al. EP Europace (2021)..

Hubert Cochet ^{1,2*}, Yosuke Nakatani³, Soumaya Sridi-Cheniti²,




Acute Esophageal Injuries on LGE CMR

Oesophagus

CMR imaging was performed before, acutely (<3h) and 3mo post-ablation (18 PFA; 23 thermal ablation)

No esophageal lesions were observed in PFA patients

Thermal methods induced high rates of esophageal lesions (43%)







Stenosi delle vene polmonari

Ostial dimensional changes after pulmonary vein isolation: Pulsed field ablation vs radiofrequency ablation

Kuroki et al. Heart rhythm 17.9 (2020): 1528-1535.

PV Stenosis: EAM and CT at 3-months post-PVI

- No instances PV stenosis or narrowing







17° Meeting

CardioLucca
Heart Brings Heart 2023Lucca,
22-24 Giugno
2023Centro Congressi
Auditorium San Francesco

Sistema nervoso autonomo





17° Meeting


CardioLucca
Heart Brings Heart 2023



Lucca,
22-24 Giugno
2023

Centro Congressi
Auditorium San Francesco

Coronary Spasm During Pulsed Field Ablation of the Mitral Isthmus Line



JACC CE 2021;12:1618-27



17° Meeting

CardioLucca
Heart Brings Heart 2023



Lucca,
22-24 Giugno
2023

Centro Congressi
Auditorium San Francesco


Circulation: Arrhythmia and Electrophysiology


ORIGINAL ARTICLE



Paroxysmal Atrial Fibrillation Ablation Using a Novel Variable-Loop Biphasic Pulsed Field Ablation Catheter Integrated With a 3-Dimensional Mapping System: 1-Year Outcomes of the Multicenter insPIRE Study

Mattias Duytschaever^{1,2}, MD, PhD; Tom De Potter^{1,2}, MD; Massimo Grimaldi^{1,2}, MD, PhD; Ante Anic^{1,2}, MD; Johan Vijgen³, MD; Petr Neuzil⁴, MD, PhD; Hugo Van Herendael, MD; Atul Verma⁵, MD; Allan Skanes⁶, MD; Daniel Scherr, MD; Helmut Pürerfellner⁷, MD; Gediminas Rackauskas⁸, MD; Pierre Jaïs⁹, MD; Vivek Y. Reddy¹⁰, MD; on behalf of the insPIRE Trial Investigators*







17° Meeting

CardioLucca


Heart Brings Heart 2023




Lucca,
22-24 Giugno
2023


Centro Congressi
Auditorium San Francesco


Adverse events*	Wave I (n=40)	Wave II (n=186)
PAE†	0 (0)	0 (0)
Atrioesophageal fistula	0 (0)	0 (0)
Cardiac tamponade/perforation	0 (0)	0 (0)
Pulmonary vein stenosis	0 (0)	0 (0)
Device- or procedure-related death	0 (0)	0 (0)
Major vascular access complication/bleeding	0 (0)	0 (0)
Myocardial infarction	0 (0)	0 (0)
Pericarditis	0 (0)	0 (0)
Phrenic nerve paralysis (permanent)	0 (0)	0 (0)
Stroke/cerebrovascular accident	0 (0)	0 (0)
Thromboembolism	0 (0)	0 (0)
Transient ischemic attack	0 (0)	0 (0)
Pulmonary vein stenosis subanalysis‡		
Mild	0 (0)	NA
Moderate	0 (0)	NA
Severe	0 (0)	NA



Circ Arrhythm Electrophysiol. 2023;16:e011780










17° Meeting
CardioLucca
Heart Brings Heart 2023



Lucca,
22-24 Giugno
2023

Centro Congressi
Auditorium San Francesco





17° Meeting

CardioLucca
Heart Brings Heart 2023



Lucca,
22-24 Giugno
2023
Centro Congressi
Auditorium San Francesco

IMPULSE, PEFCAT, PEFCAT II

Pulsed Field Ablation of Paroxysmal Atrial Fibrillation

1-Year Outcomes of IMPULSE, PEFCAT, and PEFCAT II

121 patients with **paroxysmal AF** were treated with PFA (3 centers, 5 operators)

- IMPULSE (40 pts; NCT03700385)
- PEFCAT (71 pts; NCT03714178)
- PEFCATII (10 pts; NCT04170608)

Waveform

- Monophasic PFA: 15 patients
- Early biphasic PFA: 57 patients
- Optimized biphasic PFA: 49 patients


TABLE 1 Patient Characteristics

	Total Cohort (N = 121)	Optimized Waveform Cohort (n = 49)
Age, yrs	57.4 ± 10.3	56.9 ± 10.4
Male	89 (73.6)	32 (65.3)
LA diameter, mm	40.5 ± 4.5	40.0 ± 5.0
LVEF, %	62.5 ± 5.7	61.2 ± 7.2
Sleep apnea	4 (3.3)	2 (4.1)
COPD	4 (3.3)	0 (0.0)
Hypertension	68 (56.2)	29 (59.2)
Diabetes	11 (9.1)	3 (6.1)
Dyslipidemia	41 (33.9)	17 (34.7)
Stroke or TIA	6 (5.0)	3 (6.1)
CAD (MI/CABG)	4 (3.3)	2 (4.1)
Antiarrhythmics	118 (97.5)	49 (100.0)
Class I	83 (68.6)	38 (77.6)
Class III	23 (19.0)	8 (16.3)
Beta-blockers	44 (36.4)	18 (36.7)



IMPULSE, PEFCAT, PEFCAT II

PFA Catheter & Mechanism of Ablation




Safety

- *Esophageal Damage* 0%
- *Esophageal Dysmotility* 0%
- *Atrioesophageal Fistula* 0%
- *Pulmonary Vein Stenosis* 0%
- *Phrenic Nerve Injury* 0%
- *Stroke* 0%
- *Transient Ischemic Attack* 0.9%
- *Pericardial Effusion* 0.8%
- *Vascular injury* 1.7%
- *Death* 0%

Efficacy

Durability of PV Isolation (Invasive Remapping)

PFA Waveform	Per PV Basis		Per Pt Basis	
	No.%	Durable	No.%	Durable
All	429	84.8%	110	64.5%
PFA-OW	173	96.0%	44	84.1%






PFA in persistent AF


Pulsed Field Ablation in Patients With Persistent Atrial Fibrillation

Vivek Y. Reddy, MD,^{a,b} Ante Anic, MD,^c Jacob Koruth, MD,^b Jan Petru, MD,^a Moritoshi Funasako, MD,^a Kentaro Minami, MD,^a Toni Breskovic, MD, PhD,^c Ivan Sikiric, MD,^c Srinivas R. Dukkipati, MD,^b Iwanari Kawamura, MD,^b Petr Neuzil, MD, PhD^a




Posterior wall isolation


FIGURE 4 Durability of Posterior Wall PFA





Multi-national survey on the methods, efficacy, and safety on the post-approval clinical use of pulsed field ablation (MANIFEST-PF)



Findings from repeat ablation using high-density mapping after pulmonary vein isolation with pulsed field ablation



Findings from repeat ablation using high-density mapping after pulmonary vein isolation with pulsed field ablation




Study on Optimal Parameter and Target for Pulsed-Field Ablation of Atrial Fibrillation

Xuying Ye^{1,2}, Shangzhong Liu³, Huijuan Yin⁴, Qiang He², Zhixiao Xue^{3,5*}, Chengzhi Lu^{1,2*} and Siying Su⁵

 frontiers
in Cardiovascular Medicine

September 2021 | Volume 8 |
Article 690092



Energia

Dimensioni elettrodi




Distanza fra elettrodi

Durata singolo impulso

Numero impulsi

Numero di treni di
impulsi

Intervallo fra treni di
impulsi





17° Meeting


CardioLucca
Heart Brings Heart 2023



Lucca,
22-24 Giugno
2023


Centro Congressi
Auditorium San Francesco

STAR for PVI in elderly



Catheter ablation for atrial fibrillation in the elderly >75 years old: Systematic review and meta-analysis

Complication rates



J Cardiovasc Electrophysiol. 2022;33:1435–1449.



17° Meeting


CardioLucca Heart Brings Heart 2023




Lucca,
22-24 Giugno
2023


Centro Congressi
Auditorium San Francesco

STAR for PVI in elderly



Di Monaco A. Circ Arrhythm Electrophysiol. 2022;15:e010880





17° Meeting



CardioLucca

Heart Brings Heart 2023

Lucca, 22-24 Giugno 2023

Centro Congressi Auditorium San Francesco

Grazie per l'attenzione!